Drug intelligence / Profile preview

bispecific antibody + activated T cells

Development stage: Unknown
Lead developer: Benhealth Biopharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cell Therapies
Administration: Intravenous

Overview

Bispecific antibody + activated T cells (BATs) is a combination immunotherapy platform being developed by Benhealth Biopharmaceutical, specifically for the treatment of refractory or relapsed leukemia in pediatric patients. The approach involves the ex vivo activation and expansion of T cells, which are then 'armed' by coating them with a bispecific antibody. This antibody is designed to bridge the activated T cells (typically via the CD3 receptor) to tumor-associated antigens on the surface of leukemia cells. This interaction triggers the direct cytotoxic activity of the T cells against the tumor, independent of MHC restriction. The program is currently in clinical development in collaboration with Sun Yat-sen Memorial Hospital.

Other names: Bispecific Antibody-armed Activated T cellsBATsBispecific Antibody + Activated T Cells pediatric

Targets

CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)CD38 (Cluster of Differentiation 38)MUC1 (Mucin-1 Antigen)EPCAM (Epithelial cell adhesion molecule)ERBB2 (Erb-b2 receptor tyrosine kinase 2)GPC3 (Glypican-3)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on bispecific antibody + activated T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bispecific antibody + activated T cells.

Explore the full profile